1. Encelto has been approved by the US FDA as the first treatment for Macular Telangiectasia type 2 (MacTel). 
2. Encelto delivers sustained therapeutic doses of ciliary neurotrophic factor (CNTF) to the retina.
3. Phase 3 trial data for Encelto showed significant slowing of macular photoreceptor loss over 24 months.
4. MacTel is a rare, progressive neurodegenerative disease of the retina that leads to central vision loss.
5. Approximately 0.1% of the population in the U.S. around 250,000 people, are estimated to have MacTel.
6. Encelto is expected to be available in the United States in June 2025.

Source: Retinal Physician